ACE2 and metabolic dysfunction-associated steatotic liver disease: Several studies have suggested that local hepatic ACE2 overexpression and blockers of AngII and ATR1 can be used in the prevention and treatment of diabetes, insulin resistance, glucose homeostasis, hepatic steatosis, NAFLD, liver fibrosis and other metabolic disorders [2,16,33,34,39,40].